CureVac AG - Germany
Ingmar Hoerr founded the biopharmaceutical company CureVac in the year 2000 in Tuebingen. His entrepreneurship was motivated by a surprising discovery during his doctoral research. Experiments conducted for his research showed that the mRNA molecule class can be directly injected into tissue and is capable of expressing genes into proteins effectively as well as generating a strong specific immune response, contrary to what had previously been believed.
From this key discovery, in his role as CEO he built up a company that was the first ever to treat a human subject with an mRNA drug and that is now a leading biopharmaceutical company. Since its inception, CureVac has received approximately €400m in equity investments.
Ingmar Hoerr received his Ph.D. from the University of Tübingen and his MBA from Danube University, Krems, Austria. He currently advises the European Commission as member of the EIC Advisory Board and is juror of the founder prize Weconomy. He recently served on the Founding Board of Agency of Disruptive Innovations.